Personal information

Websites & social links

University Hospital Basel, Medical Oncology
Department Biomedicine UNIBAS
Binder lab

Other IDs

SciProfiles: 2010849

Activities

Collapse all

Employment (1)

University Hospital of Basel: Basel, CH

2023-01-04 to present (Medical Oncology)
Employment
Source: Self-asserted source
Mascha Binder

Professional activities (5)

Sachsen-Anhaltische Krebsgesellschaft: Halle, DE

Membership
Source: Self-asserted source
Mascha Binder

Hamburger Krebsgesellschaft: Hamburg, DE

Membership
Source: Self-asserted source
Mascha Binder

European Society for Medical Oncology: Lugano, Ticino, CH

Membership
Source: Self-asserted source
Mascha Binder

European Hematology Association: Den Haag, Zuid-Holland, NL

Membership
Source: Self-asserted source
Mascha Binder

Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie: Berlin, DE

Membership
Source: Self-asserted source
Mascha Binder

Funding (22)

Evolutionäre ´dead-ends´ als Biomarker für Immun Checkpoint Blockade

2022 to 2025 | Grant
Deutsche Krebshilfe (Bonn, DE)
Source: Self-asserted source
Mascha Binder

Phase 2 multicenter study investigating the tolerability and efficacy of UV1 vaccine in patients with recurrent or metastatic PD-L1 positive (CPS≥1) head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab

2021 to 2024 | Grant
Innovation Fund of Norwegian Government (Oslo, NO)
Source: Self-asserted source
Mascha Binder

TARC: Chemoradiotherapy phase 1 trial for patients with rectal cancer and liquid biopsy monitoring

2020 to 2024 | Grant
Servier (Paris, FR)
Source: Self-asserted source
Mascha Binder

A Phase II, randomized (1:1) open label study to assess the efficacy and safety of eltrombopag in combination with dexamethasone compared to dexamethasone, as first-line treatment in adult patients with newly diagnosed immune thrombocytopenia (ITP)

2020 to 2023 | Grant
Novartis Pharma (Basel, DE)
Source: Self-asserted source
Mascha Binder

IMSTAR: Immunotherapy Phase 2 Trial in curative setting in patients with head and neck cancer

2019 to 2023 | Grant
Bristol-Myers Squibb Foundation (NY, NY, US)
Source: Self-asserted source
Mascha Binder

INTEGA: Immunotherapy phase 2 trial in patients with HER2 positive gastric and gastroesophageal junction cancer

2019 to 2022 | Grant
AIO-Studien (Berlin, DE)
Source: Self-asserted source
Mascha Binder

RAP: Immunotherapy phase 2 trial in relapsed patients with HER2 negative gastric cancer

2019 to 2022 | Grant
AIO-Studien (Berlin, DE)
Source: Self-asserted source
Mascha Binder

immunomonitor

2019 to 2021 | Grant
Eurostars (Brüssel, BE)
Source: Self-asserted source
Mascha Binder

B-cells in autoimmune liver disease (P01*)

2018-01-01 to present | Grant
German Research Foundation (Bonn, DE)
URL: https://app.dimensions.ai/details/grant/grant.7212294
GRANT_NUMBER: 396771791
Source: Self-asserted source
Mascha Binder via DimensionsWizard

AVETUX: Immunotherapy trial for patients with metastatic colorectal cancer

2018 to 2021 | Grant
AIO-Studien (Berlin, DE)
Source: Self-asserted source
Mascha Binder

Platform for the development of immunoncological antibodies

2017 to 2019 | Grant
profi der ifb (Hamburg, DE)
Source: Self-asserted source
Mascha Binder

The BCR as tumor promoter in CLL and MCL

2017 to 2019 | Grant
Deutsche Forschungsgemeinschaft (Bonn, DE)
Source: Self-asserted source
Mascha Binder

B cell in autoimmune hepatitis

2017 to 2017 | Grant
Deutsche Forschungsgemeinschaft SFB 841 (Bonn, DE)
Source: Self-asserted source
Mascha Binder

The B-cell receptor as tumor promotor in chronic lymphocytic leukemia and mantle cell lymphoma

2016-01-01 to 2021-12-31 | Grant
German Research Foundation (Bonn, DE)
URL: https://app.dimensions.ai/details/grant/grant.6458439
GRANT_NUMBER: 321118409
Source: Self-asserted source
Mascha Binder via DimensionsWizard

Characterization of resistance-mediating mutations in the extracellular domain of the EGFR in colorectal and head and neck cancer

2016 to 2021 | Grant
Deutsche Forschungsgemeinschaft (Bonn, DE)
Source: Self-asserted source
Mascha Binder

NGS mmune profiling for response prediction to immune checkpoint inhibitors

2015 to 2016 | Grant
Hilgemann Foundation (Hamburg, DE)
Source: Self-asserted source
Mascha Binder

Characterization of resistance-mediating mutations in the extracellular domain of the EGFR in colorectal and head and neck cancer I

2014 to 2016 | Grant
Deutsche Forschungsgemeinschaft (Bonn, DE)
Source: Self-asserted source
Mascha Binder

Neoepitope profiling in multiple myeloma

2014 to 2016 | Grant
Deutsche Krebshilfe (Bonn, DE)
Source: Self-asserted source
Mascha Binder

Characterization of potential resistance-mediating mutations of the EGFR ectodomain in patients with colorectal and head and neck cancer

2013-01-01 to 2021-12-31 | Grant
German Research Foundation (Bonn, DE)
URL: https://app.dimensions.ai/details/grant/grant.4839519
GRANT_NUMBER: 243019617
Source: Self-asserted source
Mascha Binder via DimensionsWizard

Characterization of tumor-initiating cells in myeloma

2012 to 2014 | Grant
Wilhelm Sander-Stiftung (München, DE)
Source: Self-asserted source
Mascha Binder

Characterisation of the BCR-epitope interaction in CLL

2010 to 2012 | Grant
José Carreras Leukämie-Stiftung (München, DE)
Source: Self-asserted source
Mascha Binder

Characterization and therapeutic targeting of precursor B cells in multiple myeloma

2010 to 2012 | Grant
Wilhelm Sander-Stiftung (München, DE)
Source: Self-asserted source
Mascha Binder

Peer review (2 reviews for 1 publication/grant)

Review activity for Immunity. (2)
How many people are using ORCID?